Company profile: Zedira
1.1 - Company Overview
Company description
- Provider of transglutaminase-focused biotech solutions, including specialty reagents for R&D and diagnostics; small-molecule drug candidates such as ZED1227 for celiac disease; fee-for-service transglutaminase activity measurement; recombinant microbial transglutaminase (Andracon) for ADC production; diagnostic antigens (TG2, TG3, TG6, DGPs); and an Anti-TG6 ELISA kit.
Products and services
- ZED1227: Clinical-stage drug candidate for celiac disease that is undergoing clinical trials specifically evaluating therapeutic efficacy and patient safety outcomes
- Diagnostic Antigens: High-quality antigens for celiac disease diagnostics, encompassing TG2, TG3, TG6, and DGPs to support transglutaminase-focused research and diagnostic testing
- Anti-TG6-ELISA: Proprietary ELISA kit that detects autoantibodies against neuronal transglutaminase TG6, enabling targeted measurement of TG6-specific autoantibodies in research and diagnostic settings
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Zedira
BCF Life Sciences
HQ: France
Website
- Description: Provider of natural amino acids and derivatives for the pharmaceutical and health care industries. Specialises in extracting L-Cystine and L-Tyrosine of 100% traced origin and derivatives such as Carbocisteine. Offers L-Cystine, L-Tyrosine, Carbocisteine (expectorant API), Cysti-White, Kera-Diet keratin hydrolysate, and Leafamine (17 free amino acids) for food supplements, baby foods, and sustainable agriculture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BCF Life Sciences company profile →
Neothetics
HQ: United States
Website
- Description: Provider of clinical-stage specialty pharmaceutical therapeutics for the aesthetic market.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neothetics company profile →
ArcticZymes Technologies
HQ: Norway
Website
- Description: Provider of enzymes and kits for medical research, developed and manufactured by a biotechnology company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArcticZymes Technologies company profile →
Arzeda
HQ: United States
Website
- Description: Provider of AI-driven protein and enzyme design and manufacturing for pharmaceuticals, industrial chemicals, and food applications. Offers Intelligent Protein Design Technology to create novel proteins; ProSweet enzymes for efficient production of Reb D and Reb M from stevia; and collaborates with Unilever (cleaning), W. L. Gore (materials), Takeda (therapeutic biologics), and AAK (plant-based oils).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arzeda company profile →
Remedy Plan
HQ: United States
Website
- Description: Provider of pre-clinical cancer therapeutics developing first-in-class small molecule drugs that differentiate cancer cells, including RPT1G, a clinical candidate targeting NAMPT for solid and hematological malignancies. Offers NAMPT programs in oncology, autoimmune, and obesity, and a proprietary high-throughput phenotypic drug screening platform targeting critical pathways in cancer stem cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Remedy Plan company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Zedira
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Zedira
2.2 - Growth funds investing in similar companies to Zedira
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Zedira
4.2 - Public trading comparable groups for Zedira
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →